Summary
Johnson & Johnson (JNJ) has finalized its divestiture of its remaining stake in its former Consumer Health business, now operating as Kenvue Inc. The company announced on May 17, 2024, that it completed a Debt-for-Equity Exchange. In this transaction, JNJ exchanged its remaining 182.3 million shares of Kenvue Common Stock for $3.6 billion aggregate principal amount of commercial paper that it had issued on May 15, 2024. This exchange effectively settles the commercial paper and marks the complete exit of Johnson & Johnson from its ownership of Kenvue. This strategic move concludes Johnson & Johnson's long-planned separation of its consumer health division. The initial separation began with Kenvue's IPO in May 2023, followed by a significant exchange offer in August 2023 that reduced JNJ's stake substantially. The final exchange of shares for debt removes any lingering ownership ties and allows Johnson & Johnson to fully focus on its pharmaceutical and medtech segments. Investors should view this as a significant step in JNJ's strategic realignment.
Key Highlights
- 1Johnson & Johnson (JNJ) has completed the divestiture of its entire remaining stake in Kenvue Inc.
- 2The final separation was achieved through a Debt-for-Equity Exchange completed on May 17, 2024.
- 3JNJ exchanged 182,329,550 shares of Kenvue Common Stock for $3.6 billion of its own commercial paper.
- 4The $3.6 billion in commercial paper was issued on May 15, 2024, with net proceeds intended for general corporate purposes.
- 5Upon completion of the exchange, the commercial paper was satisfied and discharged.
- 6Johnson & Johnson no longer owns any shares of Kenvue Common Stock, marking a full exit from the consumer health business.